Library

Challenges in estimating the impact of pneumococcal conjugate vaccines through surveillance. / A. Vergison in Pediatric Infectious Disease, 31(2012)4 ([04/01/2012])  

[article] Challenges in estimating the impact of pneumococcal conjugate vaccines through surveillance. [printed text] / A. Vergison, Author ; Germaine Hanquet, Author . - 2012 . - 400-3. Languages : English (eng) in Pediatric Infectious Disease > 31(2012)4 [04/01/2012] . - 400-3 Descriptors: Classification W 1 Serials. Periodicals Indexation Child ; Peer Review ; Pneumococcal Vaccines ; Vaccines Conjugate Link for e-copy: http://journals.lww.com/pidj/Citation/2012/04000/Challenges_in_Estimating_the_Im [...] Format of e-copy: PDF [Requires Subscription] Record link: https://kce.docressources.info/index.php?lvl=notice_display&id=2970 [article]

Convincing or confusing? / Philippe Beutels in Vaccine, 25(2007)8 ([02/09/2007])  

[article] Convincing or confusing? : Economic evaluations of childhood pneumococcal conjugate vaccination [printed text] / Philippe Beutels, Author ; Nancy Thiry, Author ; Pierre Van Damme, Author . - 2007 . - 1355-1367. Research Support, Non-U.S. Gov't Review Languages : English (eng) in Vaccine > 25(2007)8 [02/09/2007] . - 1355-1367 Descriptors: Classification W 1 Serials. Periodicals Indexation Child, Preschool ; Economics ; Humans ; immunology ; Infant ; Journal Article ; Netherlands ; Peer Review ; Pneumococcal Infections ; Pneumococcal Vaccines ; prevention and control ; Vaccines Conjugate Abstract: We review 15 economic analyses of pneumococcal conjugate vaccines, published between 2002 and 2006, in terms of methodology, assumptions, results and conclusions. We found a great diversity in assumptions (eg, vaccine efficacy parameters, incidence rates for both invasive and non-invasive disease) mainly due to local variation in data and opinions. Accordingly, the results varied greatly, from total net savings to over euro 100,000 per discounted QALY gained. The cost of the vaccination program (determined by price per dose and schedule (4 or 3 doses, or fewer)), and likely herd immunity impacts are highly influential though rarely explored in these published studies. If the net long-term impact (determined by a mixture of effects related to herd immunity, serotype replacement, antibiotic resistance and cross reactivity) remains beneficial and if a 3-dose schedule confers near-equivalent protection to a 4-dose schedule, the cost-effectiveness of PCV7 vaccination programs can be viewed as attractive in developed countries. Link for e-copy: http://tiny.cc/aalwe Format of e-copy: VDIC IP recognition Record link: https://kce.docressources.info/index.php?lvl=notice_display&id=1767 [article]

Cost-effectiveness of 10- and 13-valent pneumococcal conjugate vaccines in childhood / Philippe Beutels / Brussels [Belgium] : KCE = Federaal Kenniscentrum voor de Gezondheidszorg = Centre Fédéral d'Expertise des Soins de Santé = Belgian Health Care Knowledge Centre (2011)  

Cost-effectiveness of 10- and 13-valent pneumococcal conjugate vaccines in childhood [printed text] / Philippe Beutels, Author ; Adriaan Blommaert, Author ; Germaine Hanquet, Author ; J Bilcke, Author ; Nancy Thiry, Author ; Martine Sabbe, Author ; J. Verhaegen, Author ; F De Smet, Author ; Michael Callens, Author ; Pierre Van Damme, Author . - Brussels [Belgium] : KCE = Federaal Kenniscentrum voor de Gezondheidszorg = Centre Fédéral d'Expertise des Soins de Santé = Belgian Health Care Knowledge Centre, 2011 . - VIII, 101 p. : ill. ; A4. - (KCE Reports. Health Technology Assessment (HTA); 155C) . ISSN : D/2011/10.273/21 : € 0,00 Study 2009-52 (HTA): Incremental cost-effectiveness of the 7, 10 and 13-valent pneumococcal conjugate vaccines Languages : English (eng) Descriptors: Classification WC 217 Pneumococcal infections Indexation 2009-52 ; Cost-Benefit Analysis ; Infant ; Pneumococcal Infections ; Pneumococcal Vaccines ; R155 ; Vaccines Conjugate Contents note: LIST OF TABLES 3-- LIST OF FIGURES 5-- GLOSSARY 6-- 1 BACKGROUND 7-- 1.1 THE SEVEN-VALENT CONJUGATE PNEUMOCOCCAL VACCINE 7-- 1.2 TWO NEW CONJUGATE PNEUMOCOCCAL VACCINES 8-- 2 OBJECTIVES AND RESEARCH QUESTIONS 9-- 3 LITERATURE SEARCHES AND METHODS 10-- 4 IMMUNOGENICITY, EFFICACY AND EFFECTIVENESS OF CURRENT-- PNEUMOCOCCAL CONJUGATE VACCINES 13-- 4.1 SEVEN VALENT PNEUMOCOCCAL CONJUGATE VACCINE (PCV7) 13-- 4.1.1 Clinical trials – efficacy of PCV7 13-- 4.1.2 Post-licensure studies – effectiveness of PCV7 14-- 4.1.3 Pathogenicity of serotypes 21-- 4.2 TEN VALENT PNEUMOCOCCAL CONJUGATE VACCINE (PCV10) 22-- 4.2.1 Clinical trials – immunogenicity of PCV10 22-- 4.2.2 Clinical trials – efficacy of PCV10 24-- 4.3 THIRTEEN VALENT PNEUMOCOCCAL CONJUGATE VACCINE (PCV13) 25-- 4.3.1 Clinical trials – immunogenicity of PCV13 25-- 5 DISEASE BURDEN IN BELGIUM 27-- 5.1 INVASIVE PNEUMOCOCCAL DISEASE (IPD) 28-- 5.2 ACUTE OTITIS MEDIA (AOM) AND COMMUNITY ACQUIRED PNEUMONIAE (CAP) 35-- 5.3 HOSPITALISATIONS 36-- 5.3.1 Meningitis hospitalisations 36-- 5.3.2 Bacteremia and septicaemia hospitalisations 38-- 5.3.3 Pneumonia hospitalisations 39-- 5.4 DEATHS 39-- 5.4.1 Invasive pneumococcal diseases (IPD) deaths 39-- 5.4.2 (Pneumococcal) pneumonia deaths 40-- 5.4.3 Pneumococcal meningitis deaths 40-- 5.4.4 Pneumococcal septicaemia deaths 41-- 6 ECONOMIC EVALUATIONS OF PCV10 AND PCV13 42-- 6.1 MODELS STRUCTURE 42-- 6.2 MAIN ASSUMPTIONS AND RESULTS 43-- 7 MATHEMATICAL MODELS OF PNEUMOCOCCAL TRANSMISSION 46-- 8 COST-UTILITY ANALYSIS OF PCV10 AND PCV13 IN BELGIUM 48-- 8.1 STUDY DESIGN 48-- 8.1.1 General 48-- 8.1.2 Vaccination options 48-- 8.1.3 Mathematical model structure 49-- 8.2 MODEL INPUT DATA 50-- 8.2.1 Epidemiological parameters and transition probabilities 50-- 8.2.2 Vaccine efficacy estimates 52-- 8.2.3 Direct costs 61-- 8.2.4 Health-Related Quality of Life 63-- 8.3 RESULTS 64-- 8.3.1 Cost-effectiveness acceptability curves 64-- 8.3.2 Incremental costs, outcomes and cost-effectiveness ratios 68-- 8.3.3 Further scenario analyses 77-- 8.3.4 Influence of vaccine price and of inclusion or exclusion of AOM 77-- 8.3.5 Influence of serotype replacement and herd immunity assumptions 79-- 8.3.6 Joint influence of vaccine price, expected serotype replacement and of the additional-- effectiveness of PCV10 versus PCV13 against otitis media 79-- 8.3.7 Budget impact analysis 82-- 9 CONCLUSION 83-- 10 APPENDICES: ADDITIONAL COST-EFFECTIVENESS ACCEPTABILITY-- CURVES 86-- 11 REFERENCES 88 Link for e-copy: https://kce.fgov.be/sites/default/files/page_documents/kce_155c_pneumococcal_vac [...] Record link: https://kce.docressources.info/index.php?lvl=notice_display&id=2572

Copies

Barcode	Call number	Media type	Location	Section	Status
No copy

Economic evaluations of pneumococcal vaccination strategies in adults / Nancy Thiry in Acta Clinica Belgica, 60(2005)6 ([11/02/2005])  

[article] Economic evaluations of pneumococcal vaccination strategies in adults : A summary of the results [printed text] / Nancy Thiry, Author ; Philippe Beutels, Author ; Pierre Van Damme, Author . - 2005 . - 338-344. Languages : Dutch (dut) English (eng) French (fre) in Acta Clinica Belgica > 60(2005)6 [11/02/2005] . - 338-344 Descriptors: Classification W 1 Serials. Periodicals Indexation Adult ; Aged ; Belgium ; Cost-Benefit Analysis ; Economics ; Humans ; Journal Article ; Middle Aged ; Peer Review ; Pneumococcal Infections ; Pneumococcal Vaccines ; prevention and control ; Vaccination Abstract: With the view to re-evaluate the current evidence about the efficiency of adult pneumococcal vaccination, we searched the Medline database to collect recent full economic evaluations on this topic. We included a literature review based on studies published up to June 2001 and 5 other studies published between July 2001 and April 2004. Based on these articles' results, pneumococcal vaccination of the elderly aged between 65 and 75 years is found to be relatively cost-effective for the health care payer. There is also evidence that vaccination of HIV+ patients and of young military personnel may be justifiable on the basis of economic evaluation including direct medical costs only. Conclusions about universal vaccination of younger adults ( Link for e-copy: http://webpublishing.schaubroeck.be/dmp/printflo/content/8/3/navigatie.aspx Format of e-copy: PDF [Open Access] Record link: https://kce.docressources.info/index.php?lvl=notice_display&id=1769 [article]

Impact of conjugate 7-valent vaccination in Belgium: addressing methodological challenges. / Germaine Hanquet in Vaccine, 29(2011)16 ([04/05/2011])  

[article] Impact of conjugate 7-valent vaccination in Belgium: addressing methodological challenges. [printed text] / Germaine Hanquet, Author ; Tinne Lernout, Author ; Anne Vergison, Author ; J. Verhaegen, Author ; Esther Kissling, Author ; David Tuerlinckxf, Author ; Anne Malfroot, Author ; B. Swennen, Author ; Martine Sabbe, Author . - 2011 . - 2856-64. Languages : English (eng) in Vaccine > 29(2011)16 [04/05/2011] . - 2856-64 Descriptors: Classification W 1 Serials. Periodicals Indexation Belgium ; Epidemiology ; Journal Article ; Peer Review ; Pneumococcal Vaccines ; Vaccines Conjugate Abstract: In Belgium, the 7-valent pneumococcal conjugate vaccine (PCV7) was introduced into the national schedule in 2007. The early impact of PCV7 vaccination on paediatric invasive disease was estimated by comparing pre- and post-vaccination incidence from national surveillance. In children Link for e-copy: Pneumococcal conjugate vaccine; Surveillance; Epidemiology Format of e-copy: VDIC IP recognition Record link: https://kce.docressources.info/index.php?lvl=notice_display&id=2717 [article]

Kosteneffectiviteit van 10- en 13-valent geconjugeerde pneumokokkenvaccins bij kinderen / Philippe Beutels / Brussels [Belgium] : KCE = Federaal Kenniscentrum voor de Gezondheidszorg = Centre Fédéral d'Expertise des Soins de Santé = Belgian Health Care Knowledge Centre (2011)  

Permalink

Pneumococcal serotypes in children in 4 European countries / Germaine Hanquet in Emerging Infectious Diseases, 16(2010)09 ([09/01/2010])  

Permalink

Pneumokokkenvaccinatie bij ouderen / Adriaan Blommaert / Brussels [Belgium] : KCE = Federaal Kenniscentrum voor de Gezondheidszorg = Centre Fédéral d'Expertise des Soins de Santé = Belgian Health Care Knowledge Centre (2016)  

Permalink

Quelle vaccination contre le pneumocoque chez les personnes âgées ? / Adriaan Blommaert / Brussels [Belgium] : KCE = Federaal Kenniscentrum voor de Gezondheidszorg = Centre Fédéral d'Expertise des Soins de Santé = Belgian Health Care Knowledge Centre (2016)  

Permalink

Rapport coût-efficacité des vaccins antipneumococciques conjugués 10- valent et 13-valent chez l’enfant / Philippe Beutels / Brussels [Belgium] : KCE = Federaal Kenniscentrum voor de Gezondheidszorg = Centre Fédéral d'Expertise des Soins de Santé = Belgian Health Care Knowledge Centre (2011)  

Permalink

Recommendations for the use of the 23-valent polysaccharide pneumococcal vaccine in adults: / W.E. Peetermans in Acta Clinica Belgica, 60(2005)6 ([11/02/2005])  

Permalink

Surveillance of invasive pneumococcal disease in 30 EU countries / Germaine Hanquet in Vaccine, 28(2010)23 ([05/21/2010])  

Permalink

Temporal trends of invasive Streptococcus pneumoniae serotypes and antimicrobial resistance patterns in Spain from 1979 to 2007 / Asuncion Fenoll in Journal of clinical microbiology, 47(2009)4 ([04/01/2009])  

Permalink

Use of pneumococcal vaccines in the elderly / Adriaan Blommaert / Brussels [Belgium] : KCE = Federaal Kenniscentrum voor de Gezondheidszorg = Centre Fédéral d'Expertise des Soins de Santé = Belgian Health Care Knowledge Centre (2016)  

Permalink

Use of pneumococcal vaccines in the elderly / Adriaan Blommaert / Brussels [Belgium] : KCE = Federaal Kenniscentrum voor de Gezondheidszorg = Centre Fédéral d'Expertise des Soins de Santé = Belgian Health Care Knowledge Centre (2016)  

Permalink